Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study
Ying Cheng, Qiming Wang, Kai Li, Jianhua Shi, Ying Liu, Lin Wu, Baohui Han, Gongyan Chen, Jianxing He, Jie Wang, Donghua Lou, Hao Yu, Shan-chun Wang, Haifeng Qin, Xiaoling Li
Topics & Concepts
PlaceboHazard ratioMedicineInternal medicineClinical endpointConfidence intervalLung cancerGastroenterologyChemotherapySurgeryClinical trialPathologyAlternative medicineLung Cancer Research StudiesCancer therapeutics and mechanismsPeptidase Inhibition and Analysis